214147-60-1

Basic information

• Product Name: 2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester
• Synonyms: Tert-butyl 2-chloro-1h-benzo[d]iMidazole-1-carboxylate
• CAS NO: 214147-60-1
• Molecular Formula: C₁₂H₁₃ClN₂O₂
• Molecular Weight: 252.69682
• Mol File: 214147-60-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 367.5±25.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 1.03±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester(214147-60-1)
• EPA Substance Registry System: 2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester(214147-60-1)

Safety Data

• Hazardous Substances Data: 214147-60-1(Hazardous Substances Data)

Usage

General Description

2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester is a complex organic compound that falls within the category of benzimidazoles. This type of chemicals encompasses a range of substances that can display a broad array of biological activities, making them integral to certain pharmaceuticals and therapies. The specific compound has a chlorine atom and a tert-butyl ester attached to its benzimidazole structure. It's utilized in the field of chemistry as an important intermediate for the synthesis of other chemicals or compounds. Its detailed properties may vary and would be determined experimentally or through specific analytical calculations.

Upstream product

• 4857-06-1 2-chloro-1H-benzoimidazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 256527-06-7 tert-butyl 2-[(2S)-2-[(benzyloxy)carbonyl]-1-piperidinyl]-1H-1,3-benzimidazole-1-carboxylate 
• 851597-48-3 2-(2,6-dimethyl-phenoxy)-1H-benzoimidazole 
• 851597-50-7 2-(2-methoxy-phenoxy)-1H-benzoimidazole 

Relevant articles and documents

TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF

Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a

Light Induced C-C Coupling of 2-Chlorobenzazoles with Carbamates, Alcohols, and Ethers

A light induced, transition-metal-free C-C coupling reaction of 2-chlorobenzazoles with aliphatic carbamates, alcohols, and ethers is presented. Inexpensive reagents, namely sodium acetate, benzophenone, water, and acetonitrile, are employed in a simple reaction protocol using a cheap and widely available 25 W energy saving UV-A lamp at ambient temperature.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to hydroxybenzimidazole pyrimidines or pyridines or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.